[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100467423":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":7,"centralContacts":8,"locations":17,"responsibleParty":34,"collaborators":7,"id":38,"slug":39,"hasResults":40,"nctId":41,"briefTitle":42,"officialTitle":43,"acronym":7,"eligibilityCriteria":44,"healthyVolunteers":40,"sex":45,"minAge":46,"maxAge":47,"enrollmentInfo":48,"targetDuration":7,"studyType":51,"phases":7,"briefSummary":52,"conditions":53,"keywords":7,"overallStatus":20,"whyStopped":7,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":66},{"fullName":5,"class":6},"Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia","OTHER",null,[9,14],{"name":10,"role":11,"phone":12,"phoneExt":7,"email":13},"Domenico Russo, MD","CONTACT","00390303996811","domenico.russo@unibs.it",{"name":15,"role":11,"phone":12,"phoneExt":7,"email":16},"Mirko Farina, MD","m.farina004@unibs.it",[18],{"facility":19,"status":20,"city":21,"state":7,"zip":22,"country":23,"countryCode":24,"cosmosGeoPoint":25,"geoPoint":30,"contacts":31},"ASST Spedali Civili di Brescia","RECRUITING","Brescia","25123","Italy","IT",{"type":26,"coordinates":27},"Point",[28,29],10.21472,45.53558,{"lat":29,"lon":28},[32,33],{"name":10,"role":11,"phone":12,"phoneExt":7,"email":13},{"name":15,"role":11,"phone":12,"phoneExt":7,"email":16},{"type":35,"investigatorFullName":36,"investigatorTitle":37,"investigatorAffiliation":5,"oldNameTitle":7,"oldOrganization":7},"PRINCIPAL_INVESTIGATOR","Prof Domenico Russo","Head of Clinical Unit; Clinical Professor;","100467423","bio-car-t-bs-study-100467423",false,"NCT05366569","Bio-CAR-T BS Study","Bio-CAR-T Study on Pre and Post-infusion CAR-T Cell Therapy","Inclusion Criteria:\n\n* Patients with B-cell-ALL (≤ 25 years) or patients with DLBCL (18-70 years) or patients with PMBCL (18-70 years) who were relapsed\u002Frefractory after two lines of treatments;\n* Adequate performance status (0 or 1);\n* Adequate organ function;\n* No active or uncontrolled infections;\n* No thrombo-embolisms within the last 6 months;\n* Absence of clinically relevant co-morbidities (e.g., select cardiovascular, neurologic, or immune disorders with organ dysfunction or requiring immunosuppressive treatment in the last 24 months);\n* Life expectancy of at least 3 months.\n\nExclusion Criteria:\n\n* Patients with B-cell-ALL \\> 25 years\n* Patients with DLBCL \\\u003C18 or \\>70 years\n* Patients with PMBCL \\\u003C18 or \\>70 years\n* Performance status \\> 1;\n* Active or uncontrolled infections;\n* Thrombo-embolisms within the last 6 months;\n* Presence of clinically relevant co-morbidities (e.g., select cardiovascular, neurologic, or immune disorders with organ dysfunction or requiring immunosuppressive treatment in the last 24 months);\n* Life expectancy \\\u003C 3 months.","ALL","18 Years","70 Years",{"count":49,"type":50},45,"ESTIMATED","OBSERVATIONAL","The aim of this Study is the evaluation of post-infusion CAR-T (Chimeric Antigen Receptor T Cell) expansion and persistence in patients with DLBCL, PMBCL and ALL undergoing CAR-T therapy; and the feasibility and efficacy of the treatment in the real life practice.",[54,55,56],"Diffuse Large B Cell Lymphoma (DLBCL)","Primary Mediastinal Large B-cell Lymphoma (PMBCL)","Acute Lymphoblastic Leukemia (ALL)","2026-04-27",{"date":59,"type":60},"2026-04-30","ACTUAL",{"date":62,"type":60},"2022-04-26",{"date":64,"type":50},"2026-12-31",{"name":5,"class":6},1]